Cargando…

Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need

Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of the extremities. While MFS is rarely metastasizing, it shows an extremely high rate of multiple fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanni, Silvia, Fausti, Valentina, Fonzi, Eugenio, Liverani, Chiara, Miserocchi, Giacomo, Spadazzi, Chiara, Cocchi, Claudia, Calabrese, Chiara, Gurrieri, Lorena, Riva, Nada, Recine, Federica, Casadei, Roberto, Pieri, Federica, Guerrieri, Ania Naila, Serra, Massimo, Ibrahim, Toni, Mercatali, Laura, De Vita, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138892/
https://www.ncbi.nlm.nih.gov/pubmed/37108089
http://dx.doi.org/10.3390/ijms24086926
_version_ 1785032814810365952
author Vanni, Silvia
Fausti, Valentina
Fonzi, Eugenio
Liverani, Chiara
Miserocchi, Giacomo
Spadazzi, Chiara
Cocchi, Claudia
Calabrese, Chiara
Gurrieri, Lorena
Riva, Nada
Recine, Federica
Casadei, Roberto
Pieri, Federica
Guerrieri, Ania Naila
Serra, Massimo
Ibrahim, Toni
Mercatali, Laura
De Vita, Alessandro
author_facet Vanni, Silvia
Fausti, Valentina
Fonzi, Eugenio
Liverani, Chiara
Miserocchi, Giacomo
Spadazzi, Chiara
Cocchi, Claudia
Calabrese, Chiara
Gurrieri, Lorena
Riva, Nada
Recine, Federica
Casadei, Roberto
Pieri, Federica
Guerrieri, Ania Naila
Serra, Massimo
Ibrahim, Toni
Mercatali, Laura
De Vita, Alessandro
author_sort Vanni, Silvia
collection PubMed
description Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of the extremities. While MFS is rarely metastasizing, it shows an extremely high rate of multiple frequent local recurrences (50–60% of cases). On the other hand, UPS is an aggressive sarcoma prone to distant recurrence, which is correlated to a poor prognosis. Differential diagnosis is challenging due to their heterogeneous morphology, with UPS remaining a diagnosis of exclusion for sarcomas with unknown differentiation lineage. Moreover, both lesions suffer from the unavailability of diagnostic and prognostic biomarkers. In this context, a genomic approach combined with pharmacological profiling could allow the identification of new predictive biomarkers that may be exploited for differential diagnosis, prognosis and targeted therapy, with the aim to improve the management of STS patients. RNA-Seq analysis identified the up-regulation of MMP13 and WNT7B in UPS and the up-regulation of AKR1C2, AKR1C3, BMP7, and SGCG in MFS, which were confirmed by in silico analyses. Moreover, we identified the down-regulation of immunoglobulin genes in patient-derived primary cultures that responded to anthracycline treatment compared to non-responder cultures. Globally, the obtained data corroborated the clinical observation of UPS as an histotype refractory to chemotherapy and the key role of the immune system in determining chemosensitivity of these lesions. Moreover, our results confirmed the validity of genomic approaches for the identification of predictive biomarkers in poorly characterized neoplasms as well as the robustness of our patient-derived primary culture models in recapitulating the chemosensitivity features of STS. Taken as a whole, this body of evidence may pave the way toward an improvement of the prognosis of these rare diseases through a treatment modulation driven by a biomarker-based patient stratification.
format Online
Article
Text
id pubmed-10138892
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101388922023-04-28 Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need Vanni, Silvia Fausti, Valentina Fonzi, Eugenio Liverani, Chiara Miserocchi, Giacomo Spadazzi, Chiara Cocchi, Claudia Calabrese, Chiara Gurrieri, Lorena Riva, Nada Recine, Federica Casadei, Roberto Pieri, Federica Guerrieri, Ania Naila Serra, Massimo Ibrahim, Toni Mercatali, Laura De Vita, Alessandro Int J Mol Sci Article Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of the extremities. While MFS is rarely metastasizing, it shows an extremely high rate of multiple frequent local recurrences (50–60% of cases). On the other hand, UPS is an aggressive sarcoma prone to distant recurrence, which is correlated to a poor prognosis. Differential diagnosis is challenging due to their heterogeneous morphology, with UPS remaining a diagnosis of exclusion for sarcomas with unknown differentiation lineage. Moreover, both lesions suffer from the unavailability of diagnostic and prognostic biomarkers. In this context, a genomic approach combined with pharmacological profiling could allow the identification of new predictive biomarkers that may be exploited for differential diagnosis, prognosis and targeted therapy, with the aim to improve the management of STS patients. RNA-Seq analysis identified the up-regulation of MMP13 and WNT7B in UPS and the up-regulation of AKR1C2, AKR1C3, BMP7, and SGCG in MFS, which were confirmed by in silico analyses. Moreover, we identified the down-regulation of immunoglobulin genes in patient-derived primary cultures that responded to anthracycline treatment compared to non-responder cultures. Globally, the obtained data corroborated the clinical observation of UPS as an histotype refractory to chemotherapy and the key role of the immune system in determining chemosensitivity of these lesions. Moreover, our results confirmed the validity of genomic approaches for the identification of predictive biomarkers in poorly characterized neoplasms as well as the robustness of our patient-derived primary culture models in recapitulating the chemosensitivity features of STS. Taken as a whole, this body of evidence may pave the way toward an improvement of the prognosis of these rare diseases through a treatment modulation driven by a biomarker-based patient stratification. MDPI 2023-04-08 /pmc/articles/PMC10138892/ /pubmed/37108089 http://dx.doi.org/10.3390/ijms24086926 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vanni, Silvia
Fausti, Valentina
Fonzi, Eugenio
Liverani, Chiara
Miserocchi, Giacomo
Spadazzi, Chiara
Cocchi, Claudia
Calabrese, Chiara
Gurrieri, Lorena
Riva, Nada
Recine, Federica
Casadei, Roberto
Pieri, Federica
Guerrieri, Ania Naila
Serra, Massimo
Ibrahim, Toni
Mercatali, Laura
De Vita, Alessandro
Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title_full Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title_fullStr Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title_full_unstemmed Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title_short Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
title_sort unveiling the genomic basis of chemosensitivity in sarcomas of the extremities: an integrated approach for an unmet clinical need
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138892/
https://www.ncbi.nlm.nih.gov/pubmed/37108089
http://dx.doi.org/10.3390/ijms24086926
work_keys_str_mv AT vannisilvia unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT faustivalentina unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT fonzieugenio unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT liveranichiara unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT miserocchigiacomo unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT spadazzichiara unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT cocchiclaudia unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT calabresechiara unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT gurrierilorena unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT rivanada unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT recinefederica unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT casadeiroberto unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT pierifederica unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT guerrierianianaila unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT serramassimo unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT ibrahimtoni unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT mercatalilaura unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed
AT devitaalessandro unveilingthegenomicbasisofchemosensitivityinsarcomasoftheextremitiesanintegratedapproachforanunmetclinicalneed